Amato Giaccia
Founder at Arresto BioSciences, Inc.
Net worth: 150 492 $ as of 2023-12-30
Amato Giaccia active positions
| Companies | Position | Start | End |
|---|---|---|---|
Arresto BioSciences, Inc.
 Arresto BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Arresto Biosciences, Inc. is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. The company was founded by Amato Giaccia, Michael T. Longaker and Geoffrey C. Gurtner in 2007 and is headquartered in Palo Alto, California. | Founder | 2009-08-13 | - |
| Stanford Cancer Institute | Corporate Officer/Principal | - | - |
| Stanford University School of Medicine | Corporate Officer/Principal | - | - |
| AKSO Biopharmaceutical, Inc. | Chairman | - | - |
| Founder | - | - |
Career history of Amato Giaccia
Former positions of Amato Giaccia
| Companies | Position | Start | End |
|---|---|---|---|
| ARAVIVE, INC. | Director/Board Member | 2018-10-11 | 2024-01-16 |
| Independent Dir/Board Member | 2018-10-11 | 2024-01-16 | |
Aravive Biologics, Inc.
 Aravive Biologics, Inc. Pharmaceuticals: MajorHealth Technology Aravive Biologics, Inc. develops novel targeted therapeutics in oncology. The company was founded by Amato Giaccia and Albert Koong and is headquartered in Houston, TX. | Director/Board Member | 2010-07-31 | 2018-10-11 |
| Chief Tech/Sci/R&D Officer | 2016-12-31 | 2018-10-11 | |
| Founder | 2010-07-31 | 2018-10-11 | |
Oxford Institute for Energy Studies
 Oxford Institute for Energy Studies Miscellaneous Commercial ServicesCommercial Services Oxford Institute for Energy Studies operates as an energy research institute. Its three main programs include oil, natural gas, and electricity. It publishes analysis of topical global energy issues across production, consumption, markets, policy and regulation. The company is headquartered in Oxford, the United Kingdom. | Director/Board Member | 2018-12-31 | - |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Director/Board Member | 2018-10-11 | - |
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Founder | 2000-12-31 | - |
Training of Amato Giaccia
| University of Pennsylvania | Doctorate Degree |
Statistics
International
| United States | 10 |
| United Kingdom | 2 |
Operational
| Founder | 4 |
| Director/Board Member | 4 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 5 |
| Commercial Services | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ARAVIVE, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Arresto BioSciences, Inc.
Arresto BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Arresto Biosciences, Inc. is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. The company was founded by Amato Giaccia, Michael T. Longaker and Geoffrey C. Gurtner in 2007 and is headquartered in Palo Alto, California. | Commercial Services |
Proacta, Inc.
Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
Aravive Biologics, Inc.
Aravive Biologics, Inc. Pharmaceuticals: MajorHealth Technology Aravive Biologics, Inc. develops novel targeted therapeutics in oncology. The company was founded by Amato Giaccia and Albert Koong and is headquartered in Houston, TX. | Health Technology |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
| Stanford Cancer Institute | |
Oxford Institute for Energy Studies
Oxford Institute for Energy Studies Miscellaneous Commercial ServicesCommercial Services Oxford Institute for Energy Studies operates as an energy research institute. Its three main programs include oil, natural gas, and electricity. It publishes analysis of topical global energy issues across production, consumption, markets, policy and regulation. The company is headquartered in Oxford, the United Kingdom. | Commercial Services |
| AKSO Biopharmaceutical, Inc. |
- Stock Market
- Insiders
- Amato Giaccia
- Experience
